Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential pralatrexate versus observation after CHOP response in newly diagnosed peripheral T-cell lymphoma
2010-022230-81Phase 3Completed
- Sponsor
- Allos Therapeutics
- Start
- Nov 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in peripheral T-cell lymphoma (PTCL) comparing Sequential pralatrexate with Observation (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Nov 2010; status: completed.
02
Drugs
pralatrexate
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2010-022230-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022230-81.